header


09:00 12:00
NIMH SATELLITE SYMPOSIUM: CNS AND MYELOID CELL RESERVOIRS
Chairs: Jeymohan JOSEPH, Division of AIDS Research, NIMH - USA Mario STEVENSON, University of Miami - USA


09:00
09:15
Session Goals and NIMH Research Priorities in CNS and Myeloid Reservoirs
Jeymohan JOSEPH, AIDS Research, NIMH - USA


09:15
09:30
Unexpected Outcomes in the Rebound Zone: Utilizing Correlative PET/CT and Multi-Scale Imaging to Define SIV Rebound After ART Cessation
Thomas HOPE, Northwestern University - USA


09:30
09:45
Macrophage-tropic HIV-1 variants populate plasma viremia in chronic and acute subjects undergoing analytic treatment interruption
Viviane MACHADO, University of Miami - USA


09:45
10:00
Evidence of HIV Persistence in Circulating Myeloid Cells: Implications for HIV-associated Complications and Remission
Brooks MITCHELL, University of Hawaii at Manoa - USA


10:00
10:15
Genetic and functional differences in the CNS vs systemic HIV-1 reservoirs
Maria GONZALEZ PEREZ, University of Massachusetts Medical School - USA


10:15
10:30
HIV-infected macrophages evade NK cell-mediated killing while driving inflammation
Kiera CLAYTON, Ragon Institute - USA


11:00
11:15
Targeting lncRNA SAF to induce apoptosis in HIV-1 infected macrophages
Tsaikat BOLIAR, Cornell University - USA


11:15
11:30
Low-level Persistent/Latent HIV-1 Infection of Macrophages Corresponds to Decreased NF-kB Activity
Tim HANLEY, University of Utah Health Sciences Center - USA


11:30
11:45
Effects of Blocking NOX Signaling on HIV Persistence and HIV-associated Neurocognitive Dysfunction in a Murine HAND Model
Christina GAVEGNANO, Emory University - USA


11:45
12:00
Detection and modulation of HIV reservoirs in HIV infected patients on ART
Avi NATH, NIH - USA


09:00
01:30
MEETING OF THE MARTIN DELANEY COLLABORATORIES COMMUNITY ADVISORY BOARD


02:00
03:30
NIAID SATELLITE SYMPOSIUM: MARTIN DELANEY COLLABORATORIES RESEARCH HIGHLIGHTS (SESSION 1)


02:00
02:30
DARE Collaboratory
  • Introduction
    Steven DEEKS, University of California, San Francisco - USA
  • Engaging CD8+ T cell responses in SIV Reservoir Reduction or Reactivation Control
    Afam OKOYE, Oregon Health & Science University - USA


02:30
03:00
BEAT-HIV Collaboratory
  • Introduction
    Luis MONTANER, The Wistar Institute - USA
  • Peripheral Blood SIV/HIV Originates from Infected Cells in Tissues
    Leticia KURI-CERVANTES, University of Pennsylvania - USA
  • Contribution of Antigenic Exposure to the Persistence of HIV-Infected CD4+ T Cells In Vivo
    Francesco R. SIMONETTI, Johns Hopkins University - USA


03:00
03:30
BELIEVE Collaboratory
  • Introduction
    R. Brad JONES, Weill Cornell Medicine – USA
  • Combination IL-15 Therapy in a SHIV NHP Model
    James B. WHITNEY, Beth Israel Deaconess Medical Center - USA


04:00
05:30
NIAID SATELLITE SYMPOSIUM: MARTIN DELANEY COLLABORATORIES RESEARCH HIGHLIGHTS (SESSION 2)


04:00
04:30
I4C Collaboratory
  • Introduction
    Dan BAROUCH, Beth Israel Deaconess Medical Center - USA
  • Origin of Rebound Virus in Chronically SIV-Infected Monkeys Following Treatment Discontinuation
    Po-Ting LIU, Beth Israel Deaconess Medical Center - USA
  • HIV-1 Diversity Considerations for Clinical Studies of Passively Transferred Broadly Neutralizing Antibodies
    Kshitij WAGH, Los Alamos National Laboratory - USA


04:30
05:00
DefeatHIV Collaboratory
  • Introduction
    Hans-Peter KIEM, Fred Hutchinson Cancer Research Center - USA
  • CAR T Cell-Treated Rhesus Macaques Suppress SHIV Viremia Following ART Treatment Interruption
    Christopher PETERSON, Fred Hutchinson Cancer Research Center - USA


05:00
05:30
CARE Collaboratory
  • Introduction
    David MARGOLIS, University of North Carolina at Chapel Hill - USA
  • Novel Bivalent Chemical Degraders to Reverse HIV Latency
    Anne-Marie TURNER, UNC HIV Cure Center, University of North Carolina, Chapel Hill - USA
  • Improved Killing of HIV-infected Cells by a Combination of Three Antibodies: Implications for Clearing Persistent Infection
    Marina TUYISHIME, Department of Surgery, Duke University Medical Center, Durham, NC - USA


05:30
05:45
CanCURE Overview
Eric COHEN, IRCM, Human Retrovirology research unit, Montréal - CAN


06:00
WELCOME
Mario STEVENSON, University of Miami - USA


06:05
07:30
Opening Lecture
  • Introduction
    Chairs:
    Karl SALZWEDEL, National Institute of Allergy and Infectious Diseases, Bethesda - USA David MARGOLIS, University of North Carolina at Chapel Hill - USA
  • Ending the HIV Pandemic: Follow the Science
    Anthony S. FAUCI, National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, WA - USA
  • Bringing curative interventions for HIV to resource-limited parts of the world
    Mike McCUNE, HIV Frontiers, Global Health Innovative Technology Solutions, Bill & Melinda Gates Foundation - USA


08:00
10:00
SESSION 1: BASIC SCIENCE OF HIV LATENCY
Chairs: Jonathan KARN, Professor and Chair, Department of Molecular Biology and Microbiology, School of Medicine, Director, Case Center for AIDS Research, Cleveland/Akron, OH - USA Una O’DOHERTY, Associate Professor Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, PA - USA Christina PSOMAS, Clinical and Translational Research in the Department of Infectious Diseases of Montpellier University Hospital - FRA


OP 1.0: Cellular Mechanisms that Establish and Maintain HIV Latency
Andrew HENDERSON, Professor of Medicine, Assistant Dean Graduate Medical Sciences Department of Medicine and Microbiology, Section of Infectious Diseases Boston University School of Medicine, Boston, MA - USA


OP 1.1: Expression Profiling of HIV Latently-Infected Cells Using Nanostring And Mass Cytometry
Author(s): H. Sperber ¹, ²,*, T. Ma ³, N.R. Roan ³, S.K. Pillai ¹
  • 1Vitalant Research Institute - San Francisco (USA)
    2Free University of Berlin - Berlin (GER)
    3Gladstone Institutes - San Francisco (USA)


OP 1.2: A quantitative single cell, single molecule RNA-FISH+IF and single cell RNA-seq analysis reveals stochasticity of reactivation of latent provirus.
Author(s): G. Kalpana 1,* , R. Pathak 1, A. La Porte 1, E. Bock 1, C. Eliscovich 1, L. Martins 2, A. Spivac 2, U. Dixit 1, V. Planelles 2, R. Singer 1
  • 1Albert Einstein College of Medicine - New York (USA)
    2University of Utah School of Medicine - Salt Lake City (USA)


OP 1.3 : Single-cell transcriptome sequencing of latently-infected cells ex vivo using PCRactivated cell sorting (PACS).
Author(s): I. Clark 1, 2,*, A. Abate 1, F. Quintana 2, S. Deeks 1, D. Douek 3, E. Boritz 3,*
  • 1UCSF - San Francisco (USA)
    2Harvard - Boston (USA)
    3NIH - Bethesda (USA)


OP 1.4 : Single cell analysis of in vivo HIV reservoir uncovers novel markers of latent cells
Author(s): N. Roan 1,*, Jason Neidleman 1, 8, Xiaoyu Luo1, Julie Frouard1, 8, Feng Hsiao 1, 8, Guorui Xie 1, 8, Vincent Morcilla2, Katherine Sholtis James3, Rebecca Hoh4, Ma Somsouk5, Peter Hunt6, Steve Deeks4, Nancie Archin3, Sarah Palmer2, Warner C. Greene 1,7
  • 1Gladstone Institute of Virology and Immunology, San Francisco, CA (USA)
    2Centre for Virus Research, the Westmead Institute for Medical Research, The University of Sydney, Sydney, NSW 2145 (AUS)
    3Division of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC (USA)
    4Division of HIV, Infectious Diseases and Global Medicine, University of California San Francisco, San Francisco, CA (USA)
    5Department of Medicine, Division of Gastroenterology, San Francisco General Hospital and University of California, San Francisco, CA (USA)
    6Division of Experimental Medicine, University of California San Francisco, San Francisco, CA (USA)
    7Department of Medicine, University of California, San Francisco, CA (USA)
    8Department of Urology, University of California, San Francisco, CA (USA)


OP 1.5 : Quantifying the contribution of cellular proliferation to maintaining the HIV reservoir
Author(s): A. Hill 1,*, G. Andrei 1, J. Gerold 1
  • 1Harvard University - Cambridge, Ma (USA)


OP 1.6 : Tyrosine Kinase Inhibition: the new Front in HIV Cure Efforts.
Author(s): V. Planelles 1,*, M. Szaniawski 1, E. Williams 1, E. Innis 1, L. Martins 1, A. Spivak 1, J. Alcami 2, M. Coiras 2


10:30
12:30
SESSION 2: IN VITRO AND ANIMAL MODEL STUDIES OF HIV PERSISTENCE
Chairs:
Ann CHAHROUDI, Associate Professor of Pediatrics, Division of Pediatric Infectious Diseases, Emory University School of Medicine, Atlanta, GA - USA Afam OKOYE, Research Associate Professor Vaccine & Gene Therapy Institute, and Division of Pathobiology and Immunology, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton - USA


OP 2.0 : In vivo platforms for the evaluation of novel approaches to HIV persistence and eradication
Lecturer: J. Victor GARCIA MARTINEZ, Professor of Medicine, Center for AIDS Research, Division of Infectious Diseases, Chapel Hill - USA


OP 2.1: Understanding the establishment and persistence of the rebound competent reservoir using barcoded viruses
Lecturer: Brandon F. KEELE, AIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory, Frederick - USA


OP 2.2 : Barcoded viruses facilitate tracking changes to the composition of the rebound-competent reservoir
Author(s): T. Immonen 1,*, C. Fennessey 1, J. Lifson 1, B. Keele 1,*
  • 1AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research - Frederick (USA)


OP 2.3 : Delay in Viral Rebound with TLR7 Agonist, N6-LS and PGT121 in SHIV-infected Macaques
Author(s): D. Hsu 1,*, D. Silsorn 2, R. Imerbsin 2, A. Pegu 3, J. Mascola 3, R. Geleziunas 4, R. Koup 3, D. Barouch 5, N. Michael 6, S. Vasan
  • 1MHRP - Bangkok (THA)
    2AFRIMS - Bangkok (THA)
    3NIH - Bethesda (USA)
    4Gilead Sciences - Foster City (USA)
    5BIDMC - Boston (USA)
    6MHRP - Silver Spring (USA)


OP 2.4: Chimeric Antigen Receptor T-Cells and Stem Cells Control and Protect Against SHIV Replication in Nonhuman Primates
Author(s): C. Peterson 1,*, B. Rust 1, A. Zhen 2, K. Brandenstein 1, N. Poole 1, C. Maldini 3, G. Ellis 3, S. Kitchen 2, J. Riley 3, H.P. Kiem 1
  • 1Fred Hutchinson Cancer Research Center - Seattle (USA)
    2University of California, Los Angeles - Los Angeles (USA)
    3University of Pennsylvania - Philadelphia (USA)


OP 2.5: The latency reversal activity of the SMAC mimetic AZD5582 in ART-suppressed SIVinfected rhesus macaques is potentiated by CD8a cell depletion
Author(s): M. Mavigner 1,*, A. Brooks 1 , C. Mattingly 1 , T. Vanderford 1 , B. Keele 2 , J. Lifson 2 , R. Dunham 3 , D. Margolis 3 , G. Silvestri 1 , A. Chahroudi 1
  • 1Emory University - Atlanta (USA)
    2Frederick National Laboratory for Cancer Research - Frederick (USA)
    3UNC Chapel Hill - Chapel Hill (USA)


OP 2.6 : Utilizing correlative PET/CT and multiscale imaging to define the dynamics of SIV infected cells from early ART initiation to the rebound after analytic treatment interruption
Author(s): T. Hope 1,*, M.S. Arif 1, Y. Thomas 1, I. Clerc 1, A. Carias 1, E. Allen 1, M. Mcraven 1, M. Ramirez 2, P. Santangelo 3 , F. Villinger 2
  • 1Northwestern - Chicago (USA)
    2New Iberia Research Center - New Iberia (USA)
    3Georgia Tech - Atlanta (USA)


02:00
03:30
SESSION 3: VIROLOGY OF HIV PERSISTENCE
Chairs :
Katherine BAR, Associate professor of medicine, Perelman School of Medicine, University of Pennsylvania, USA Zabrina BRUMME, Director, Laboratory Program, BC Centre for Excellence in HIV/AIDS, Saint Paul Hospital, Vancouver - CAN


OP 3.0 : CD4-MBL-CAR/CXCR5 T cell immunotherapy shows promise at reducing SIV replication post-ART release
Lecturer: Pamela SKINNER, Professor Department of Veterinary and Biomedical Sciences Microbiology, Immunology and Cancer Biology (MICaB) Ph.D. Graduate Program, University of Minnesota, MN - USA


OP 3.1: Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy
Author(s): M. Peluso 1,*, P. Bacchetti 1 , K. Ritter 2 , S. Beg 3 , P. Hunt 1 , T. Henrich 1 , J. Siliciano 3 , R. Siliciano 3 , G. Laird 2 , S. Deeks 1
  • 1University of California, San Francisco - San Francisco (USA)
    2Accelevir Diagnostics - Baltimore (USA)
    3Johns Hopkins School of Medicine - Baltimore (USA)


OP 3.2: Women undergoing reproductive aging show increased reservoir sizes associated with removal of hormonal control of HIV-1 latency by estrogen
Author(s): J. Karn 1,*,C. Dobrowolski 1,*, E. Scully 2, K.M. Weber 3 , A.L. Landay 4
  • 1Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine - Cleveland (USA)
    2Johns Hopkins University, Department of Medicine, Division of Infectious Diseases - Baltimore (USA)
    3WIHS/CORE Center of Cook County Health - Chicago (USA)
    4Rush University Medical Center, Department Internal Medicine - Chicago (USA)


OP 3.3: Contribution of Antigenic Exposure to the Persistence of HIV-infected CD4+ T-cells in vivo
Author(s): F. Simonetti 1,*, H. Zhang 1, G. Soroosh 1, S. Beg 1, H. Raymond 2, K. Mccormick 2, S. Deeks 3, F. Bushman 2, J. Siliciano 4, R. Siliciano 1
  • 1Johns Hopkins University - Baltimore (USA)
    2University of Pennsylvania - Philadelphia (USA)
    3University of California San Francisco - San Francisco (USA)
    4Johns Hoppkins University - Baltimore (USA)


OP 3.4: Multiplexed RNA flow cytometric FISH allows single-cell viral transcriptional profiling and phenotypic characterization of translation-incompetent HIV reservoirs
Author(s): M. Dubé 1,*, D. Kaufmann 1,*, G. Sannier 1 , N. Brassard 1 , G.G. Delgado 1 , A. Baxter 1 , J.P. Routy 2 , N. Chomont 1
  • 1Research Centre of the Centre Hospitalier de l’Université de Montréal (CRCHUM) and Université de Montréal, Montreal, Quebec, Canada - Montréal (CAN)
    2Chronic Viral Illnesses Service and Division of Hematology, McGill University Health Centre - Montréal (CAN)


OP 3.5: Low Viral Reservoir Treated Individuals Show Unusual HIV Latency Distribution
Author(s): C. Gálvez 1,*, V. Urrea 1, S. Benet 1, B. Mothe 1, L. Bailón 2, J. Dalmau 1, L. Leal 3, F. García 3, J. Martinez-Picado 1, M. Salgado 1
  • 1AIDS Research Institute IrsiCaixa - Badalona (SPA)
    2Infectious Diseases Department, University Hospital “Germans Trias i Pujol” - Badalona (SPA)
    3Infectious Diseases Department, Hospital Clínic, University of Barcelona - Barcelona (SPA)


08:00
10:00
SESSION 4: IMMUNOLOGY OF HIV PERSISTENCE
Chairs :
Lydie TRAUTMANN, Associate Professor, OHSU, Vaccine & Gene Therapy Institute, Beaverton - USA R. Brad JONES, Assistant Professor, Department of Medicine, Weill Cornell Medicine, New York, NY - USA


OP 4.0: CellulaT Cells and The Cure Agenda
Lecturer: Bruce WALKER, Founding Director of the Ragon Institute of MGH, MIT and Harvard and the Director of the Harvard University Center for AIDS Research, Cambridge, MA - USA


OP 4.1: HIV persistence during ART: Keeping memory, keeping HIV
Lecturer: Nicolas CHOMONT, Associate Professor in the Department of Microbiology and Immunology at the Université de Montréal – CHUM Research Center, Montreal - CAN


OP 4.2: Characterizing “exceptional” control among HIV elite controllers
Author(s): M. Peluso 1,*, P. Burbelo 2, S. Kumar 1 S. Munter 1, R. Hoh 1, S. Lee 1, P. Hunt 1, R. Rutishauser 1, T. Henrich 1, S. Deeks 1
  • 1University of California, San Francisco - San Francisco (USA)
    2National Institutes of Health - Bethesda (USA)


OP 4.3: Single-cell TCR sequencing reveals that clonally expanded cells highly contribute to the inducible HIV reservoir during ART
Author(s): P. Gantner 1,*, A. Pagliuzza 2, M. Pardons 1, M. Ramgopal 3, J.P. Routy 3, R. Fromentin 2, N. Chomont 1
  • 1Université de Montréal - Montréal (CAN)
    2CRCHUM - Montréal (CAN)
    3Midway Immunology & Research Center - Fort Pierce (USA)


OP 4.4: Single-cell phenotyping of HIV-infected expanded clones in ART-suppressed individuals
Author(s): C. Dufour 1,*, M. Pardons 1, R. Fromentin 1, M. Massanella 1, S. Palmer 2, S. Deeks 3, B. Murrell 4, J.P. Routy 5, N. Chomont 1
  • 1Centre de Recherche du CHUM and Department of Microbiology, Infectiology and Immunology, Université de Montréal - Montreal (CAN)
    2Centre for Virus Research, The Westmead Institute of Medical Research, The University of Sydney - Sydney (AUS)
    3Department of Medicine, University of California San Francisco - California (USA)
    4Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet - Stockholm (SWE)
    5Division of Hematology & Chronic Viral Illness Service, McGill University Heath Centre - Montreal (CAN)


OP 4.5: The IciStem consortium: T-cell immunology in HIV-1 infected individuals after allogeneic stem cell transplantation
Author(s): J. Martinez-Picado 3,*J. Eberhard 1,*, M. Angin 2, C. Passaes 2, M. Salgado 3, J.L. Díez Martín 4, M. Nijhuis 5, A. Wensing 5, J. Schulze Zur Wiesch 1, A. Sáez-Cirión 2
  • 1Department of Medicine, Infectious Diseases Unit, University Medical Center Hamburg-Eppendorf - Hamburg (GER)
    2Institut Pasteur, HIV, Inflammation and Persistence - Paris (FRA)
    3AIDS Research Institute IrsiCaixa - Barcelona (SPA)
    4Hospital Universitario Gregorio Marañón, Instituto de Investigación Sanitarias Gregorio Marañón, Universidad Complutense - Madrid (SPA)
    5University Medical Center - Utrecht (NET)


OP 4.6: Dynamics of HIV-Specific T-Cells on Long-Term ART Differ by Antigen Recognized and by Sex
Author(s): Eva M. Stevenson1, Adam R. Ward1,2,3, Thomas R. Dilling1, John K. Bui1, John Mellors4, Rajesh Gandhi5, Deborah McMahon4, Joseph Eron6, Ronald Bosch7, Christina Lalama7, Joshua Cyktor4, and Brad Jones1,2, for the A5321 Team
  • 1Division of Infectious Diseases, Weill Cornell Medicine, New York, NY (USA)
    2Department of Microbiology, Immunology, and Tropical Medicine, George Washington University, Washington, DC (USA)
    3PhD program in Epidemiology, George Washington University, Washington, DC (USA)
    4University of Pittsburgh, Pittsburgh, PA (USA)
    5Massachusetts General Hospital, Boston, MA (USA)
    6University of North Carolina, Chapel Hill, NC (USA)
    7Harvard University, Boston, MA (USA)


10:30
12:30
SESSION 5: HUMAN STUDIES AND DRUG DEVELOPMENT I
Chairs :
Bonnie HOWELL, Executive Director, Infectious Disease and Vaccines Merck, West Point, Pennsylvania, PE - USA Javier MARTINEZ PICADO, ICREA Research Professor at Institut de Recerca de la Sida - IrsiCaixa, Barcelona – SPA


OP 5.0: Discovery and development of novel latency reversing agents
Lecturer: Richard DUNHAM, Scientific Leader and Fellow at ViiV Healthcare; Adj Asst Professor at UNC-CH Région de Raleigh-Durham, NC - USA


OP 5.1: Virologic Outcomes of Vesatolimod Administration in People Living with HIV on ART
Lecturer: Joseph HESSELGESSER, Research scientist, Gilead, Foster city, CA - USA


OP 5.2: HIV Post-Treatment Control Despite Plasma Viral Evolution and Dual Infection
Author(s): J. Li 1*, B. Etemad 1, G. Namazi 1, Y. Wen 2, N. Jilg 3, E. Esmaeilzadeh 1, X. Zhang 4, R. Sharaf 1, Z. Brumme 5, M. Kearney 6
  • 1Brigham and Women’s Hospital, Harvard Medical School - Boston (USA)
    2China Medical University - Shenyang (CHI)
    3Massachusetts General Hospital, Harvard Medical School - Boston (USA)
    4Beijing Friendship Hospital - Beijing (CHI)
    5Simon Fraser University - Burnaby (CAN), 6Frederick National Laboratory for Cancer Research - Frederick (USA)


OP 5.3: Optimization of Smac Mimetics as HIV-1 Latency Reversing Agents
Author(s): L. Pache 1,*, P. Teriete 1, M.D. Marsden 2, A.M. Spivak 3, D. Heimann 1, A.J. Portillo 1, V. Planelles 3, J.A. Zack 2, N.D.P. Cosford 1, S.K. Chanda 1
  • 1Sanford Burnham Prebys Medical Discovery Institute - La Jolla (USA)
    2University of California, Los Angeles - Los Angeles (USA)
    3University of Utah School of Medicine - Salt Lake City (USA)


OP 5.4: HIV Particles Expressed in Semen under INSTI-based Suppressive Therapy are Largely Myeloid Cell-Derived and Exhibit Widely Diverse Genotypes
Author(s): J. Johnson 1,*, D. Anderson 2 , J.F. Li 1 , A. Santos Tino 3 , J. Politch 2 , J. Lipscomb 1 , J. Defelice 4 , M. Gelman 4 , K. Mayer 4
  • 1CDC, Atlanta (USA)
    2BU School of Medicine, Boston (USA)
    3The DESA Group, Atlanta, USA 4The Fenway Institute,Boston (USA)


OP 5.5: Impact of anti-PD-1 and anti-CTLA-4 on the HIV reservoir in vivo: The AMC-095 Study
Author(s): Thomas A Rasmussen1, Laskhmi Rajdev2, Ajantha Rhodes1, Ashanti Dantanarayana1, Surekha Tennakoon1, Socheata Chea1, Danielle Rigau3, Shelly Lensing4, Rachel Rutishauser5, Sonia Bakkour6, Michael Busch6, Dirk P Dittmer7, Steven Deeks5, Christine Durand3, Sharon R Lewin1, 8 3
  • 1The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Melbourne, (AUS)
    2Department of Medicine, Albert Einstein College of Medicine, New York (USA)
    3Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland (USA)
    4Department of Biostatistics, University of Arkansas for Medical Biosciences, Arkansas (USA)
    5Department of Medicine, University of California San Francisco, California (USA)
    6Vitalant Research Institute, San Francisco, California (USA)
    7Department of Microbiology and Immunology, University of North Carolina (USA)
    8Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne (AUS)


OP 5.6: Intact Proviral DNA Levels Decline in People with HIV on Antiretroviral Therapy (ART)
Author(s): J. Cyktor 2,*, R. Gandhi 1,*, R. Bosch 3, H. Mar 3, G. Laird 4, B. Macatangay 2, J. Eron 5, R. Siliciano 6, D. Mcmahon2, J. Mellors2
  • 1Massachusetts General Hospital - Boston (USA),
    2University of Pittsburgh - Pittsburgh (USA),
    3Harvard TH Chan School of Public Health - Boston (USA),
    4Accelevir Diagnostics - Baltimore (USA),
    5University of North Carolina - Chapel Hill (USA),


SESSION 6: NEW THERAPEUTIC APPROACHES I
Chairs :
Ya-Chi HO, Assistant Professor of Microbial Pathogenesis and Medicine; Investigator, HIV Reservoirs and Viral Eradication Transformative Science Group (Cure TSG) New Haven, CT - USA Alberto BOSQUE, Assistant Professor,Department of Microbioloy, Immunology and Tropical Medicine, George Washington Universisty, Washington, WA - USA


OP 6.0 Genome editing against HIV
Lecturer: Paula CANNON, Professor of Molecular Microbiology & Immunology; Associate Director of Cross School Programs for the MESH Academy Molecular Microbiology and Immunology, Los Angeles, CA - USA


OP 6.1: Multispecific anti-HIV duoCAR-T cell therapy mediates robust HIV suppression and elimination of HIV-infected cells in humanized mice
Author(s): K. Anthony-Gonda 1,*, A. Bardhi 2, A. Ray 2, W. Krueger 1, D. Schneider 1, Z. Zhu 1, R. Orentas 1, D. Dimitrov 3, H. Goldstein 2, B. Dropulic 1
  • 1Lentigen, a Miltenyi Biotec Company - Gaithersburg (USA)
    2Albert Einstein College of Medicine - Bronx (USA)
    3University of Pittsburg - Pittsburg (USA)


OP 6.2: Location, abundance and persistence of CAR/CXCR5 transduced T cells within lymphoid tissues of SIV-infected rhesus macaques
Author(s): H. Abdelaal 1,*, M. Pampusch 1, P. Skinner 1, E. Berger 2
  • 1University of Minnesota - Minneapolis (USA)
    2University of Minnesota - The National Institutes of Health, Bethesda, Md (USA)


OP 6.3: Combinatorial latency reversal activity of Inhibitor of Apoptosis antagonists (IAPa) with mechanistically distinct classes of HIV latency reversal agents
Author(s): S. D. Falcinelli1,3, D. M. Irlbeck1,5, A.-M. Turner1, J. Peterson1,3, F. Potjewyd2, L. I. James1,2, D. Margolis1,3,4, N. Archin1,4, R. Dunham1,5
  • 1UNC HIV Cure Center (USA)
    2Center for Integrative Chemical Biology and Drug Discovery (USA)
    3Dept. of Microbiology and Immunology (USA)
    4Dept. of Medicine University of North Carolina, Chapel Hill, NC (USA)
    5HIV Drug Discovery, ViiV Healthcare, Research Triangle Park, NC (USA)


OP 6.4: α4α7-blockade delays viral rebound in SHIV infected macaques treated with a combination of HIV bNAbs
Author(s): E. Martinelli 1,*
  • 1CBR, Population Council - New York (USA)


OP 6.5: Replacing daily cART with AAV-expressed eCD4-Ig
Author(s): M. Gardner 1,*, M. Davis-Gardner 1, M. Farzan 1
  • 1The Scripps Research Institute - Jupiter (USA)


08:00
10:00
SESSION 7: HUMAN STUDIES AND DRUG DEVELOPMENT II
Chairs:
David SMITH, University of California, San Diego School of Medicine, La Jolla - USA


OP 7.0 Main challenges of human studies in the HIV eradication field
Lecturer: Beatriz MOTHE PUJADAS, MD, PhD. Associate Investigator. HIV Unit & IrsiCaixa AIDS Research Institute. Hospital Germans Trias i Pujol. UVic-UC, Barcelona - SPA


OP 7.1 : Whole Body Imaging of HIV Persistence, Viral Biomarkers and Immune Activation
Lecturer: Timothy HENRICH, Associate Professor of Medicine at University of California, San Francisco, CA - USA


OP 7.2: Plasma and Antibody Glycomic Biomarkers of Time to HIV Rebound and Viral Setpoint
Author(s): L. Giron 1,*, E. Papasavvas 1, L. Azzoni 1 , K. Mounzer 2 , J. Kostman 2 , I. Sanne 3 , C. Firnhaber 4 , Q. Liu 1 , L. Montaner 1 , M. Abdel-Mohsen 1,*
  • 1The Wistar Institute - Philadelphia (USA)
    2Philadelphia FIGHT - Philadelphia (USA)
    3University of the Witwatersrand - Johannesburg (ZAF)
    4University of Colorado School of Medicine - Aurora (USA)


OP7.3: Single cell RNA-seq identifies host genes that correlate with HIV-1 reservoir size
Author(s): R. Thomas 1,*, A. Waickman 2, P. Ehrenberg 1, A. Geretz 1, M. Eller 1, S. Tovanabutra 1, J. Ananworanich 1, N. Chomont 3, J. Currier 2, N. Michael 1
  • 1U.S. Military HIV Research Program, Walter Reed Army Institute of Research - Silver Spring (USA)
    2Viral Diseases Branch, Walter Reed Army Institute of Research - Silver Spring (USA)
    3Université de Montréal, Faculty of Medicine - Montreal (CAN)


OP 7.4: Sex differences in the latent reservoir of virally suppressed HIV-1 infected individuals living in Rakai, Uganda
Author(s): T.C. Quinn 3,*, J. Prodger 1,*, A.M. Capoferri 2, K. Yu 1, S.J. Reynolds 3, J. Kasule 4, D. Serwadda 4, E. Scully 2, K.J. Kwon 2, A.D. Redd 3
  • 1Western University - London (CAN)
    2Johns Hopkins School of Medicine - Baltimore (USA)
    3National Institutes of Health - Baltimore (USA)
    4Rakai Health Sciences Program - Kalisizo (UGA)


OP 7.5: Clones Of HIV Infected Cells Are Widely Distributed In T Cell Subsets In Blood And In Anatomic Tissues
Author(s): F. Maldarelli 1,*, M. Gozoulis 1, X. Wu 2, L. Perez 3, R. Gorelick 4, C. Lange 1, S. Hill 1, J. Virga1, T. Uldrick 5, R. Yarchoan 6, S. Hughes 1
  • 1CCR/NCI - Frederick (USA)
    2Leidos Inc - Peoria (USA)
    3VRC/NIAID - Bethesda (USA)
    4Leidos, INC - Peoria (USA)
    5CCR/NCI - U Washington (USA)
    6CCR/NCI - Bethesda (USA)


OP 7.6: Tissue-specific differences in the mechanisms that govern HIV latency in blood, liver, gut and genital tract in ART-suppressed women
Author(s): S. Moron-Lopez 1,*, G. Xie 2, P. Kim 3, J. Wong 1, J. Price 4, N. Elnachef 4, R. Greenblatt 4, P. Tien 1, N. Roan 2, S. Yukl 1
  • 1University of California San Francisco - SFVAMC - San Francisco (USA)
    2University of California San Francisco - Gladstone Institutes - San Francisco (USA)
    3San Francisco VA Medical Center (SFVAMC) - San Francisco (USA)
    4University of California San Francisco - San Francisco (USA)


SESSION 8: NEW THERAPEUTIC APPROACHES II
Chairs:
Susanna VALENTE, Associate Professor Department of Immunology and Microbiology130 Scripps Way, 3C1, Jupiter, FL - USA Lesley de ARMAS, Department of Immunology and Microbiology, University of Miami Miller School of Medicine, Miami – USA Guido POLI, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute - ITA


OP 8.0: A viable pathway to HIV-1 remission
Lecturer: Michael FARZAN, Professor an d co-chair of the Department of Immunology and Microbiology on the Florida campus of The Scripps Research Institute, FL - USA


OP 8.1: The Human IL-15 Superagonist N803 Does Not Reverse Latency in ART-suppressed, SHIV-infected macaques
Author(s): G. Webb1,*, J. Berrocal 2 , K. Busman-Sahay 1 , S. Abdulhaqq 1 , J. Smedley 1 , J. Safrit 3 , J. Estes 1 , P. Skinner 2 , J. Sacha 1
  • 1Oregon Health and Science University - Portland (USA)
    2University of Minnesota - St. Paul (USA)
    3NantKWest - Culver City (USA)


OP 8.2: How Long is Long-term? Delivery of anti-HIV Antibodies Using AAV Vector
Author(s): J. Martinez-Navio 1,*,R. Desrosiers 1,*, S. Fuchs 1, D. Mendes 1 E. Rakasz 2, G. Gao 3, J. Lifson 4,
  • 1University of Miami - Miami (USA)
    2Wisconsin National Primate Research Center UW - Madison (USA)
    3Gene Therapy Center UMass - Worcester (USA)
    4Frederick National Laboratory for Cancer Research - Frederick (USA)


OP 8.3: Intensification of ART with ABX464 decreases the total HIV reservoir and HIV transcription initiation in CD4+ T cells from HIV-infected ART-suppressed individuals
Author(s): S. Bernal 1,*, S. Moron-Lopez 2,*, S. Bernal 1,*, J.M. Steens 3, J.K. Wong 4, J. Martinez-Picado 1, S.A. Yukl 4
  • 1IrsiCaixa AIDS Research Institute - Badalona (SPA)
    2University of California San Francisco - San Francisco (USA)
    3ABIVAX - Paris (FRA)
    4San Francisco VA Medical Center - San Francisco (USA)


OP 8.4: HIV persistence despite reservoir decay during combinatorial immunotherapy including therapeutic conserved elements (CE) DNA vaccination, αPD-1 therapy, GS-986 TLR7- agonism, and CCR5 gene-edited CD4+ T cell infusion in rhesus macaques
Author(s): S. Dross1,*, C. Peterson 2 , M. O’ Connor 1 , H. Tunggal 1 , J. Li 1 , K. Jerome 2, H.P. Kiem 2 , B. Felber 3 , J. Mullins 1 , D. Fuller 1
  • 1Department of Microbiology, University of Washington - Seattle (USA)
    2Fred Hutchinson Cancer Research Center - Seattle (USA)
    3Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute - Frederick (USA)


OP 8.5: PD-1 Blockade boost Vaccine-Induced anti-HIV responses in the absence of HIV reactivation
Author(s): M. Marin Lopez 1,*, J.-G. Prado, M. Marin Lopez 1,*, E. Jimenez-Moyano 1, D. Ouchi 1, O. Blanch-Lombarte 1, D. Gorman 2, T. Hanke 3, C. Brander 1, B. Howell 4, B. Mothe 1
  • 1IrisiCaixa - Badalona (Barcelona) (SPA)
    2Merck & Co. Inc. - Palo Alto, California (USA)
    3The Jenner Institute Nuffield Department of Medicine, University of Oxford - Oxford (GBR),
    4Department of Infectious Disease, Merck & Co. Inc. - Kenilworth, Nj (USA)


OP 8.6: Post-therapy viral set-point abatement following combined antiproliferative and immune-boosting interventions: Results: from a randomized clinical trial
Author(s): R. Sobhie Diaz 1,*, L.B. Giron 2, J. Galinskas 1, J. Hunter 1, M. Janini 1, I.L. Shytaj 3, R. Cauda 4, M.C. Sucupira 5, J. Maricato 5, A. Savarino 6
  • 1Federal University of Sao Paulo, Infectious Diseases Department - São Paulo (BRA)
    2Wistar Institute - Philadelphia (USA)
    3Heidelberg University Hospital, Department of Infectious Diseases - Heidelberg (USA)
    4Institute of Infectious Diseases, Gemelli Hospital, Catholic University of Sacred Heart - Rome (ITA)
    5Federal University of Sao Paulo, Infectious Diseases Department - São Paulo (BRA)
    6Department of Infectious Diseases, Italian Institute of Health - Rome (ITA)


OP 8.7: B cell depletion alone or in combination with IL-15 or PD-1 blockade facilitates enhanced control of virus replication in SIV-infected rhesus macaques
Author(s): Y. Fukazawa 1,*,L.J. Picker 1,*, Y. Fukazawa 1,*, H. Behrns 1 , B.E. Randall 1 , B. Varco-Merth 1 , H. Park 1 , B.K. Felber 2 , G.N. Pavlakis 2 , J.D. Lifson 3, A.A. Okoye 1
  • 1Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University - Beaverton, Or (USA)
    2Center for Cancer Research, National Cancer Institute - Frederick, Md (USA)
➤